UBS analyst Karl Keirstead upgrades DocuSign (NASDAQ:DOCU) from Sell to NeutralBy legume / April 12, 2024 / DocuSign UBS analyst Karl Keirstead upgrades DocuSign (NASDAQ:DOCU) from Sell to Neutral and raises the price target from $48 to $62.